Baseline characteristics of HPS participants by prior cerebrovascular disease
-
Upload
chanda-roberts -
Category
Documents
-
view
30 -
download
2
description
Transcript of Baseline characteristics of HPS participants by prior cerebrovascular disease
Baseline characteristics of HPS participantsby prior cerebrovascular disease
Cerebrovascular disease (3280)
No cerebrovascular disease (17 256)
Age (years) 65.5 63.7
Men 2445 (75%) 13 009 (75%)
Current smoker 534 (16%) 2379 (14%)
Coronary disease Prior MI 896 (27%) 7614 (44%)
Other CHD 564 (17%) 4312 (25%)
None 1820 (55%) 5330 (31%)
Hypertension 1655 (50%) 6802 (39%)
Baseline lipids (mmol/L) and apolipoproteins (g/L) by prior cerebrovascular disease
Cerebrovascular disease (3280)
No cerebrovascular disease (17 256)
Total cholesterol 5.9 5.8
LDL 3.4 3.4
HDL 1.08 1.05
Triglycerides 2.1 2.1
Apo A1 1.21 1.20
Apo B 1.16 1.14
Baseline lipids (mg/dL) and apolipoproteins (g/L) by prior cerebrovascular disease
Cerebrovascular disease (3280)
No cerebrovascular disease (17 256)
Total cholesterol 228 225
LDL 132 132
HDL 42 41
Triglycerides 189 189
Apo A1 1.21 1.20
Apo B 1.16 1.14
Simvastatin(40 mg daily)
vs Placebotablets
Vitamins(600 mg E, 250 mg C& 20 mg beta-carotene)
vs Placebocapsules
5 years average duration of follow-up
FACTORIAL TREATMENT COMPARISONS
(10269) (10267)
SIMVASTATIN PLACEBO Rate ratio & 95% CI
STATIN better PLACEBO better
Type
290 409Ischaemic51 53Haemorrhagic
103 134Unknown
Severity
96 119Fatal42 51Severe
107 155Moderate138 189Mild
61 71Unknown
(4.3%) (5.7%)25% SE 5reduction
444 585
(2P<0.00001)
ALL STROKES
0.4 0.6 0.8 1.0 1.2 1.4
HPS: Stroke Incidence
SIMVASTATIN PLACEBO Rate ratio & 95% CI
STATIN better PLACEBO better
Baselinefeature (10269) (10267)
Age (years)
< 65 164 195(3.3%) (4.0%)
≥ 65 < 70 110 154(4.5%) (6.3%)
≥ 70 170 236(5.8%) (8.2%)
Sex
Male 331 453(4.3%) (5.9%)
Female 113 132(4.4%) (5.2%)
ALL PATIENTS 444 585(4.3%) (5.7%)25% SE 5reduction(2P<0.00001)
0.4 0.6 0.8 1.0 1.2 1.4
HPS: STROKE incidence by AGE & SEX
(10269) (10267)
SIMVASTATIN PLACEBO Rate ratio & 95% CI
STATIN better PLACEBO better
Baselinefeature
Age
831 1091(16.9%) (22.1%)< 65
512 665(20.9%) (27.2%)65 - 69
548 620(23.8%) (27.7%)70 - 74
142 209(23.1%) (32.3%) 75
Sex
1666 2135(21.6%) (27.6%)Male
367 450(14.4%) (17.7%)Female
24% SE 3reduction(2P<0.00001)
2033 2585(19.8%) (25.2%)ALL PATIENTS
0.4 0.6 0.8 1.0 1.2 1.4
HPS: MAJOR VASCULAR EVENT by AGE & SEX
SIMVASTATIN PLACEBO Rate ratio & 95% CI
STATIN better PLACEBO better
Baselinefeature (10269) (10267)
Prior coronary disease
Yes 265 347(4.0%) (5.2%)
No 179 238(5.0%) (6.7%)
Prior cerebrovascular disease
Yes 169 170(10.3%) (10.4%)
No 275 415(3.2%) (4.8%)
Prior diabetes
Yes 149 193(5.0%) (6.5%)
No 295 392(4.0%) (5.4%)
ALL PATIENTS 444 585(4.3%) (5.7%)25% SE 5reduction(2P<0.00001)
0.4 0.6 0.8 1.0 1.2 1.4
HPS: STROKE by PRIOR DISEASE
SIMVASTATIN PLACEBO Rate ratio & 95% CI
STATIN better PLACEBO better
Baselinefeature (10269) (10267)
Prior coronary disease
Yes 175 237(2.6%) (3.5%)
No 115 172(3.2%) (4.8%)
Prior cerebrovascular disease
Yes 100 122(6.1%) (7.5%)
No 190 287(2.2%) (3.3%)
Prior diabetes
Yes 102 140(3.4%) (4.7%)
No 188 269(2.6%) (3.7%)
ALL PATIENTS 290 409(2.8%) (4.0%)30% SE 6reduction(2P<0.00001wœ4õ)
0.4 0.6 0.8 1.0 1.2 1.4
HPS: ISCHAEMIC STROKE by PRIOR DISEASE
SIMVASTATIN PLACEBO Rate ratio & 95% CISTATIN better PLACEBO better
Baselinefeature (10269) (10267)
Prior coronary disease
Yes 1459 1841(21.8%) (27.5%)
No 574 744(16.1%) (20.8%)
Prior cerebrovascular disease
Yes 406 488(24.7%) (29.8%)
No 1627 2097(18.9%) (24.3%)
Prior diabetes
Yes 601 748(20.2%) (25.1%)
No 1432 1837(19.6%) (25.2%)
ALL PATIENTS 2033 2585(19.8%) (25.2%)24% SE 3reduction(2P<0.00001)
0.4 0.6 0.8 1.0 1.2 1.4
HPS: MAJOR VASCULAR EVENTS by PRIOR DISEASE
0
10
20
30
0
10
20
30
Absolute effects on major vascular events and strokes subdivided by prior cerebrovascular disease
S
S
P
P
Yes No
Prior cerebrovascular disease
Maj
or
vas
cula
r ev
ent
(%)
Risk reductions (SE):
ProportionalAbsolute/1000P-value
20% (6)58 (18)p=0.001
25% (3) 60 (7)
p<0.0001Other event
Stroke
SIMVASTATIN PLACEBO Rate ratio & 95% CI
STATIN better PLACEBO better
Baselinefeature (10269) (10267)
LDL cholesterol (mmol/L)
< 3.0 137 194(4.0%) (5.7%)
≥ 3.0 < 3.5 108 155(4.2%) (6.2%)
> 3.5 199 236(4.6%) (5.4%)
HDL cholesterol (mmol/L)
< 0.9 170 199(4.7%) (5.6%)
≥ 0.9 < 1.1 115 166(4.1%) (5.8%)
> 1.1 159 220(4.1%) (5.7%)
ALL PATIENTS 444 585(4.3%) (5.7%)25% SE 5reduction(2P<0.00001)
0.4 0.6 0.8 1.0 1.2 1.4
HPS: STROKE incidence by BASELINE LIPIDS
SIMVASTATIN PLACEBO Rate ratio & 95% CISTATIN better PLACEBO better
Baselinefeature (10269) (10267)
LDL cholesterol (mmol/L)
< 3.0 598 756(17.6%) (22.2%)
≥ 3.0 < 3.5 484 646(19.0%) (25.7%)
> 3.5 951 1183(22.0%) (27.2%)
HDL cholesterol (mmol/L)
< 0.9 818 1064(22.6%) (29.9%)
≥ 0.9 < 1.1 560 720(20.0%) (25.1%)
> 1.1 655 801(17.0%) (20.9%)
ALL PATIENTS 2033 2585(19.8%) (25.2%)24% SE 3reduction(2P<0.00001)
0.4 0.6 0.8 1.0 1.2 1.4
HPS: MAJOR VASCULAR EVENTS by BASELINE LIPIDS
SIMVASTATIN PLACEBO Rate ratio & 95% CI
STATIN better PLACEBO better
Baselinefeature (10269) (10267)
Diastolic blood pressure (mmHg)
< 80 176 239(3.9%) (5.2%)
≥ 80 < 90 131 185(4.0%) (5.8%)
≥ 90 137 160(5.6%) (6.5%)
Systolic blood pressure (mmHg)
< 140 162 189(3.6%) (4.2%)
≥ 140 < 160 121 169(3.9%) (5.3%)
≥ 160 161 226(6.1%) (8.8%)
ALL PATIENTS 444 585(4.3%) (5.7%)25% SE 5reduction(2P<0.00001)
0.4 0.6 0.8 1.0 1.2 1.4
HPS: STROKE incidence by baselineBLOOD PRESSURE
(10269) (10267)SIMVASTATIN PLACEBO Rate ratio & 95% CI
STATIN better PLACEBO betterBaselinefeature
DBP (mmHg)
917 1210(20.4%) (26.4%)< 80
644 753(19.5%) (23.5%) 80 < 90
472 621(19.2%) (25.1%) 90
SBP (mmHg)
880 1064(19.4%) (23.5%)< 140
553 772(17.9%) (24.4%) 140 < 160
600 748(22.7%) (29.2%) 160
24% SE 3reduction(2P<0.00001)
2033 2585(19.8%) (25.2%)ALL PATIENTS
0.4 0.6 0.8 1.0 1.2 1.4
HPS: MAJOR VASCULAR EVENTS by baselineBLOOD PRESSURE
SIMVASTATIN PLACEBO Rate ratio & 95% CI
STATIN better PLACEBO better
Baselinefeature (10269) (10267)
Treated hypertension
Yes 223 274(5.3%) (6.5%)
No 221 311(3.6%) (5.2%)
Aspirin
Yes 286 378(4.4%) (5.8%)
No 158 207(4.2%) (5.5%)
ALL PATIENTS 444 585(4.3%) (5.7%)25% SE 5reduction(2P<0.00001)
0.4 0.6 0.8 1.0 1.2 1.4
HPS: STROKE incidence by TREATED HYPERTENSION and ASPIRIN USE
SIMVASTATIN PLACEBO Rate ratio & 95% CISTATIN better PLACEBO better
Baselinefeature (10269) (10267)
Treated hypertension
Yes 942 1195(22.4%) (28.1%)
No 1091 1390(18.0%) (23.1%)
Aspirin
Yes 1370 1784(21.1%) (27.4%)
No 663 801(17.5%) (21.3%)
ALL PATIENTS 2033 2585(19.8%) (25.2%)24% SE 3reduction(2P<0.00001)
0.4 0.6 0.8 1.0 1.2 1.4
HPS: MAJOR VASCULAR EVENTS by TREATED HYPERTENSION & ASPIRIN USE
SIMVASTATIN PLACEBO Rate ratio & 95% CI
STATIN better PLACEBO better
Year offollow-up (10269) (10267)
1 87 106(0.8%) (1.0%)
2 81 132(0.8%) (1.3%)
3 82 111(0.8%) (1.2%)
4 81 111(0.9%) (1.2%)
5+ 113 125(1.2%) (1.4%)
ALL PATIENTS 444 585(4.3%) (5.7%)25% SE 5reduction(2P<0.00001)
0.4 0.6 0.8 1.0 1.2 1.4
HPS : STROKE incidence by YEAR
Years of follow-up
PLACEBO
SIMVASTATIN
Benefit/1000(SE) 2(1) 7(2) 10(2) 13(3) 14(4) 15(10)
Logrank p<0.0001
0 1 2 3 4 5 60
1
2
3
4
5
6
7P
ropo
rtio
n w
ith s
trok
eHPS: STROKE by YEAR
STATIN PLACEBO Rate ratio & 95% CI
STATIN better PLACEBO better
Study
GREACE 9 17(1.1%) (2.1%)
AFCAPS/TexcAPS 14 17(0.4%) (0.5%)
Post-CABG 18 16(2.7%) (2.4%)
GISSI 20 19(0.9%) (0.9%)
WOSCOPS 46 51(1.4%) (1.5%)
CARE 52 76(2.5%) (3.7%)
SSSS 56 76(2.5%) (3.4%)
ASCOT 89 121(1.7%) (2.4%)
PROSPER 135 131(4.7%) (4.5%)
LIPID 169 204(3.7%) (4.5%)
ALLHAT 209 231(4.0%) (4.5%)
HPS 444 585(4.3%) (5.7%)
ALL PATIENTS 1261 1544(3.0%) (3.6%)21% SE 4reduction(2P<0.00001)
0.4 0.6 0.8 1.0 1.2 1.4
Effects on STROKE in major STATIN trials
HPS: Conclusions for people with cerebrovascular disease
• Lowering LDL cholesterol by 1 mmol/L (40 mg/dL) reduces the 5-year risk of ischaemic stroke by about one-quarter, with no apparent adverse effect on cerebral haemorrhage
• Similar proportional reductions in stroke risk are seen with statin therapy irrespective of age, sex, lipid levels, blood pressure, or use of other medications (including aspirin)
• Statin therapy clearly reduces the risk of major vascular events among people with pre-existing cerebrovascular disease, irrespective of the presence of coronary disease